Christopher J. Kane

25.8k total citations · 3 hit papers
423 papers, 13.2k citations indexed

About

Christopher J. Kane is a scholar working on Pulmonary and Respiratory Medicine, Surgery and Oncology. According to data from OpenAlex, Christopher J. Kane has authored 423 papers receiving a total of 13.2k indexed citations (citations by other indexed papers that have themselves been cited), including 334 papers in Pulmonary and Respiratory Medicine, 87 papers in Surgery and 84 papers in Oncology. Recurrent topics in Christopher J. Kane's work include Prostate Cancer Diagnosis and Treatment (245 papers), Prostate Cancer Treatment and Research (222 papers) and Urologic and reproductive health conditions (54 papers). Christopher J. Kane is often cited by papers focused on Prostate Cancer Diagnosis and Treatment (245 papers), Prostate Cancer Treatment and Research (222 papers) and Urologic and reproductive health conditions (54 papers). Christopher J. Kane collaborates with scholars based in United States, Canada and Japan. Christopher J. Kane's co-authors include Christopher L. Amling, Stephen J. Freedland, William J. Aronson, Martha K. Terris, Joseph C. Presti, Peter R. Carroll, Matthew R. Cooperberg, O. Fred Miller, Katherine Mallin and Prodromos G. Borboroglu and has published in prestigious journals such as Nature, New England Journal of Medicine and JAMA.

In The Last Decade

Christopher J. Kane

408 papers receiving 12.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Immunosuppressive plasma cells impede T-cell-dependent immunogenic chemotherapy

2015 429 citations Christopher J. Kane et al. profile →
Clinically Localized Prostate Cancer: AUA/ASTRO Guideline, Part I: Introduction, Risk Assessment, Staging, and Risk-Based Management

2022 226 citations Christopher J. Kane, Stephen A. Boorjian et al. The Journal of Urology profile →
Clinically Localized Prostate Cancer: AUA/ASTRO Guideline, Part II: Principles of Active Surveillance, Principles of Surgery, and Follow-Up

2022 124 citations Christopher J. Kane, Stephen A. Boorjian et al. The Journal of Urology profile →

Peers

Countries citing papers authored by Christopher J. Kane

Since Specialization

Citations

This map shows the geographic impact of Christopher J. Kane's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Christopher J. Kane with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Christopher J. Kane more than expected).

Fields of papers citing papers by Christopher J. Kane

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Christopher J. Kane. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Christopher J. Kane. The network helps show where Christopher J. Kane may publish in the future.

Co-authorship network of co-authors of Christopher J. Kane

This figure shows the co-authorship network connecting the top 25 collaborators of Christopher J. Kane. A scholar is included among the top collaborators of Christopher J. Kane based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Christopher J. Kane. Christopher J. Kane is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Difficulty With Board Certification in Urology Is Associated With Adverse Medical License Actions 2025 ·Urology Practice ·Margaret Meagher, C. E. Hall, (unknown), (unknown), E. Ann Gormley, (unknown), Christopher J. Kane	0
2	Diabetes and Prostate Cancer Outcomes in Men with Nonmetastatic Castration-Resistant Prostate Cancer: Results from the SEARCH Cohort 2023 ·Cancer Epidemiology Biomarkers & Prevention ·(unknown), (unknown), Amanda M. De Hoedt, Christopher L. Amling, William J. Aronson, Matthew R. Cooperberg, Christopher J. Kane, Zachary Klaassen, Martha K. Terris, (unknown), Stephen J. Freedland, Ilona Csizmadi	0
3	Is time to castration resistant prostate cancer a potential intermediate end-point for time to metastasis among men initiating androgen deprivation therapy for non-metastatic prostate cancer with rapid PSA doubling time (<9 months)? 2022 ·Prostate Cancer and Prostatic Diseases ·Zachary Klaassen, Lauren E. Howard, Christopher J.D. Wallis, Jessica L. Janes, Amanda M. De Hoedt, William J. Aronson, Thomas J. Polascik, (unknown), Christopher J. Kane, Matthew R. Cooperberg, Martha K. Terris, Yuan Wu, Stephen J. Freedland	1
4	Radium-223 Utilization Patterns and Outcomes in Clinical Practice 2022 ·Urology Practice ·(unknown), (unknown), Shannon Stock, Lauren E. Howard, Amanda M. De Hoedt, Martha K. Terris, Christopher L. Amling, Christopher J. Kane, Matthew R. Cooperberg, William J. Aronson, Zachary Klaassen, Thomas J. Polascik, Adriana C. Vidal, Stephen J. Freedland	1
5	African-American men with low-risk prostate cancer treated with radical prostatectomy in an equal-access health care system: implications for active surveillance 2020 ·Prostate Cancer and Prostatic Diseases ·Rishi Deka, J. Kellogg Parsons, Daniel R. Simpson, Paul Riviere, Vinit Nalawade, Lucas K. Vitzthum, A. Karim Kader, Christopher J. Kane, (unknown), James D. Murphy, Brent S. Rose	6
6	Voxel Level Radiologic–Pathologic Validation of Restriction Spectrum Imaging Cellularity Index with Gleason Grade in Prostate Cancer 2016 ·Clinical Cancer Research ·Ghiam Yamin, Natalie M. Schenker-Ahmed, Ahmed Shabaik, (unknown), Hauke Bartsch, Joshua Kuperman, Nathan S. White, Rebecca Rakow‐Penner, Kevin McCammack, J. Kellogg Parsons, Christopher J. Kane, Anders M. Dale, David S. Karow	20
7	Racial Differences in the Association Between Preoperative Serum Cholesterol and Prostate Cancer Recurrence: Results from the SEARCH Database 2016 ·Cancer Epidemiology Biomarkers & Prevention ·Emma H. Allott, Lauren E. Howard, William J. Aronson, Martha K. Terris, Christopher J. Kane, Christopher L. Amling, Matthew R. Cooperberg, Stephen J. Freedland	14
8	Predictors of Time to Metastasis in Castration-resistant Prostate Cancer 2016 ·Urology ·Daniel M. Moreira, Lauren E. Howard, (unknown), Hiruni S. Amarasekara, (unknown), (unknown), (unknown), William J. Aronson, Christopher J. Kane, Martha K. Terris, Christopher L. Amling, Matthew R. Cooperberg, (unknown), Stephen J. Freedland	56
9	Does timing of targeted therapy for metastatic renal cell carcinoma impact treatment toxicity and surgical complications? A comparison of primary and adjuvant approaches. 2016 ·PubMed ·Nishant Patel, Jason Woo, Michael A. Liss, Kerrin Palazzi, James M. Randall, Reza Mehrazin, (unknown), Hossein Mirheydar, (unknown), Hak J. Lee, Anthony L. Patterson, Christopher J. Kane, Frederick Millard, Ithaar Derweesh	12
10	Effects of Adjuvant Sorafenib and Sunitinib on Cardiac Function in Renal Cell Carcinoma Patients without Overt Metastases: Results from ASSURE, ECOG 2805 2015 ·Clinical Cancer Research ·Naomi B. Haas, Judith Manola, Bonnie Ky, Keith T. Flaherty, Robert G. Uzzo, Christopher J. Kane, Michael A.S. Jewett, Lori Wood, Christopher G. Wood, Michael B. Atkins, Janice Dutcher, George Wilding, Robert S. DiPaola	46
11	Is computed tomography a necessary part of a metastatic evaluation for castration‐resistant prostate cancer? Results from the Shared Equal Access Regional Cancer Hospital Database 2015 ·Cancer ·(unknown), Lauren E. Howard, Christopher L. Amling, William J. Aronson, Matthew R. Cooperberg, Christopher J. Kane, Martha K. Terris, Edwin M. Posadas, Stephen J. Freedland	6
12	Serum Lipid Profile and Risk of Prostate Cancer Recurrence: Results from the SEARCH Database 2014 ·Cancer Epidemiology Biomarkers & Prevention ·Emma H. Allott, Lauren E. Howard, Matthew R. Cooperberg, Christopher J. Kane, William J. Aronson, Martha K. Terris, Christopher L. Amling, Stephen J. Freedland	119
13	Postoperative statin use and risk of biochemical recurrence following radical prostatectomy: results from the S hared E qual A ccess R egional C ancer H ospital ( SEARCH ) database 2014 ·British Journal of Urology ·Emma H. Allott, Lauren E. Howard, Matthew R. Cooperberg, Christopher J. Kane, William J. Aronson, Martha K. Terris, Christopher L. Amling, Stephen J. Freedland	40
14	Initial Experience with Aspirin Use During Robotic Radical Prostatectomy 2012 ·Journal of Laparoendoscopic & Advanced Surgical Techniques ·(unknown), Ryan Kopp, Kerrin Palazzi‐Churas, Ithaar Derweesh, Christopher J. Kane	9
15	Active Surveillance for Low Risk Prostate Cancer 2011 ·The Journal of Urology ·Christopher J. Kane	1
16	Active surveillance for the management of prostate cancer in a contemporary cohort 2008 ·Cancer ·Marc Dall’Era, Badrinath R. Konety, Janet E. Cowan, Katsuto Shinohara, (unknown), Matthew R. Cooperberg, Maxwell V. Meng, Christopher J. Kane, (unknown), Viraj A. Master, Peter R. Carroll	300
17	Bladder Cancer Incidence and Risk Factors in Men With Prostate Cancer: Results From Cancer of the Prostate Strategic Urologic Research Endeavor 2007 ·The Journal of Urology ·Stephen A. Boorjian, Janet E. Cowan, Badrinath R. Konety, Janeen DuChane, Ashutosh Tewari, Peter R. Carroll, Christopher J. Kane	86
18	Effect of age on biochemical disease-free outcome in patients with T1-T3 prostate cancer treated with definitive radiotherapy in an equal-access health care system 2003 ·International Journal of Radiation OncologyBiologyPhysics ·Peter A.S. Johnstone, Robert H. Riffenburgh, Judd W. Moul, Leon Sun, Hongyu Wu, David G. McLeod, Christopher J. Kane, Douglas Martin, Leo Kusuda, Raymond Lance, Robert G. Douglas, Timothy F. Donahue, (unknown), (unknown), Andrew Chung, Douglas W. Soderdahl, (unknown), Christopher L. Amling	25
19	URETERAL STENTING AFTER URETEROSCOPY FOR DISTAL URETERAL CALCULI: A MULTI-INSTITUTIONAL PROSPECTIVE RANDOMIZED CONTROLLED STUDY ASSESSING PAIN, OUTCOMES AND COMPLICATIONS 2001 ·The Journal of Urology ·Prodromos G. Borboroglu, Christopher L. Amling, Noah S. Schenkman, Manoj Monga, John F. Ward, (unknown), Jay T. Bishoff, Christopher J. Kane	109
20	Selection: equal opportunities. 1989 ·PubMed ·Peter Murphy, Christopher J. Kane, (unknown)	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact